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‘JUST MICRO-SIZE ME’ – TINY DIABETES DEVICE TO THE 
RESCUE?
A safe, patient-friendly and non-
invasive medical device for the 
detection and screening of diabetic 
autonomic neuropathy (DAN) in 
resource-poor settings is to be marketed 
in South Africa this year, extending the 
diagnostic reach of clinicians.
Launched at the 19th World Diabetes 
Congress in Cape Town in early 
December last year, the ANSiscope is a 
patented device that won the Frost and 
Sullivan Product Innovation Award in 
Healthcare in the United States last year.
Diabetic autonomic neuropathy 
affects 40 - 60% of all diabetics and is 
commonly known as the ‘silent killer’ 
because it is so tricky to detect and can 
harm vital organs like the heart and 
kidneys. The focus generally tends to be 
on easier-to-detect sensory neuropathy 
that affects the extremities and can lead 
to amputation. With more than 3 million 
South Africans diagnosed with diabetes 
(mainly type 2), the local pandemic 
is predicted to triple in size in just 
over 2 decades due to an increasingly 
sedentary, Western way of life that is 
resulting in widespread obesity.
Diabetic neuropathies are a 
heterogeneous group of disorders 
and are among the most common 
long-term complications of diabetes, 
causing significant morbidity and 
mortality. The American Diabetes 
Association, laying down standards 
for medical care in diabetes early last 
year, recommended that screening for 
autonomic neuropathy be instituted at 
diagnosis of type 2 diabetes and 5 years 
after diagnosis of type 1.
Many type 2 diabetics remain 
undiagnosed until they develop 
complications.
India the testing ground
According to Srini Nageshwar, CEO 
of the company that developed the 
ANSiscope, over 100 of the devices, 
each costing the equivalent of about 
R25 000, have been in the field in India, 
where more than 10 000 tests had been 
done. Product and process efficacy 
proved ‘excellent’, and his company 
would begin operations in the Africa 
region, particularly South Africa, 
around June this year.
‘The machine addresses the needs of 
86% of the world for whom accessibility 
and affordability of primary health 
care is difficult. We want to transform 
primary medical diagnosis at grass-root 
levels,’ Nageshwar said.
GPs are able to begin treatment 
earlier, especially in rural areas where 
advanced medical care is negligible 
or absent. ‘For doctors who have long 
despaired about not being able to detect 
diabetes-related complications like 
DAN earlier, this provides the desired 
intervention,’ Nageshwar added.
How it works
The device measures the activity of 
both the components of the ANS – the 
sympathetic and the parasympathetic 
separately; and the balance trajectory 
between them, making the accurate 
measurement of autonomic dysfunction 
Many type 2 diabetics 
remain undiagnosed until 
they develop complications.
‘For doctors who have long 
despaired about not being 
able to detect diabetes-
related complications like 
DAN earlier, this provides 
the desired intervention,’ 
Nageshwar added.
The micro-sized diagnostic ‘ANSIscope’ tool used for detecting diabetic autonomic neuropathy.
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possible. It is reportedly the only 
medical instrument capable of doing 
so in real time (taking between 5 and 
7 minutes), and requires the patient 
to lie down during measurement at a 
sparsely equipped clinic or in a doctor’s 
rooms. The machine is particularly 
relevant given the human and economic 
costs associated with diabetes and its 
complications.
Nageshwar explained that since 
the 1930s, the variability of the RR 
intervals on an ECG were the only 
known indicator of ANS activity. 
The ANSiscope was designed using 
this premise with the measurement 
technique ‘exploiting the fractal nature 
of the RR interval time series’.
Experts at the diabetes congress in 
Cape Town warned that the disease 
posed immense social and economic 
challenges to a continent hard hit 
by HIV/AIDS. An entire 3.1% of the 
African population, or 10.4 million 
people, currently suffered from diabetes 
and this figure would double by 2025.
Minister shines SA’s marble
The congress, attended by well over 
12 000 delegates, was the largest 
medical gathering yet seen in Cape 
Town, and saw South Africa’s deputy 
health minister, Nozizwe Madlala-
Routledge, opening it and attending 
several sessions.
This was remarked on by Professor 
George Alberti, chairman of the 
organising committee and a past 
president of the International Diabetes 
Federation. ‘I’ve never known a 
politician to do this before,’ he 
enthused, adding that she had promised 
him her country would intensify the 
fight against the disease.
Madlala-Routledge subsequently 
announced that South Africa would 
lead the Group of 77 developing 
nations in getting the United Nations to 
adopt a declaration on diabetes while 
driving drug prices down. Her Director 
General, Thami Mseleku, said South 
Africa would also lead a new diabetes 
drug price war on a scale similar to that 
which saw AIDS drug costs slashed by 
over 90% over the past decade.
‘One of the things we recognise is 
that it is important for us to engage 
with the pharmaceutical and diagnostic 
industries, to impress upon them the 
need for accessible medicines and 
diagnostic tools, especially for the poor,’ 
Mseleku added.
Alberti warned that type 2 diabetes 
was occurring in younger and younger 
populations, who were getting heart 
attacks, strokes and undergoing 
amputations at the peak of their ‘life 
ability’, in their 30s, 40s and 50s. 
He said the latest figures put the 
incidence of diabetes worldwide at 
246 million, which would rise to ‘a 
very conservative’ 350 million by 2025. 
As many as 350 million people could 
already be pre-diabetic, while at least 
3 million deaths a year were ‘speeded 
up’ by the disease, although this figure 
could be as high as 10 million given 
death certification disease identification 
problems.
Dubious delights of ‘iSidudla’ 
(the plump one)
Alberti claimed that dietary change was 
‘particularly difficult’ on the southern 
African subcontinent because people 
saw putting on weight as an indication 
of success. Anyone losing weight was 
looked on ‘as probably being ill or 
poor’.
At least one local diabetes expert 
however differed, saying such attitudes 
were a not a fundamental barrier to 
combating obesity. Professor Frederick 
(Derick) Raal, Head of the Division 
of Endocrinology and Metabolism 
in the Department of Medicine at 
Johannesburg Hospital, believed the 
status attached to appearing well fed 
was ‘not as great an issue as it used to 
be’.
‘I think people realise that type 
2 diabetes is following the obesity 
pandemic. It is complicated by the 
whole HIV story because if you lose 
weight people think you’ve got the 
dreaded lurgy.’ Although proper data 
were not available, he did not really buy 
the theory that obesity was ‘promoted 
for cultural reasons’. ‘I think the spread 
of the disease has more to do with 
the change to Western lifestyles, the 
so-called Coca-Colarisation of people. 
Zulu mamas used to work the lands 
more than they do nowadays. We’ve 
engineered exercise out of our lives.’
With the new diagnostic micro-
device, it seems only engineering can 
save us from ourselves. 
Chris Bateman
‘I think the spread of the 
disease has more to do 
with the change to Western 
lifestyles, the so-called 
Coca-Colarisation of 
people. Zulu mamas used to 
work the lands more than 
they do nowadays. We’ve 
engineered exercise out of 
our lives.’
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